Pfizer Canada announced May 31, 2006 that its oral multi-targeted agent, SUTENT (sunitinib malate) has been approved by Health Canada for the treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesylate treatment due to intolerance or resistance.